Related Experiment Video
Updated: Jan 5, 2026

09:16
Author Spotlight: Investigating Angiogenesis Through Challenges and Innovations in Assay Development
Published on: May 31, 2024
2.0K
Pathological features of vessel co-option versus sprouting angiogenesis
Emily Latacz1,2,3, Elisabetta Caspani2,3, Raymond Barnhill4,5
1Iridium Kankernetwerk, Antwerp, Belgium.
Angiogenesis
|October 28, 2019
Summary
Cancer cells can hijack existing blood vessels through vessel co-option, an alternative to angiogenesis. This impacts tumor spread, patient outcomes, and treatment resistance, offering new therapeutic targets.
Area of Science:
- Oncology
- Pathology
- Cancer Biology
Background:
- Cancer cells can utilize pre-existing vasculature via vessel co-option, a process distinct from angiogenesis.
- Vessel co-option is observed across various human tumor types and tissues.
- This vascularization strategy facilitates extravascular tumor cell migration.
Purpose of the Study:
- To review the histopathological growth patterns of vessel co-option in different organs.
- To explore the clinical significance of these patterns in cancer.
- To highlight the impact of vessel co-option on patient outcomes and treatment resistance.
Main Methods:
- Histopathological analysis of vessel co-opting tumors.
- Review of existing literature on tumor vascularization and growth patterns.
- Correlation of histopathological features with clinical data.
Main Results:
- Vessel co-opting tumors exhibit distinct morphological and histopathological features compared to angiogenic tumors.
- Specific growth patterns are identified in the brain, liver, and lungs, reflecting organ-specific interactions.
- Vessel co-option is linked to patient outcomes and resistance to cancer therapies.
Conclusions:
- Histopathological patterns of vessel co-option provide insights into tumor behavior and organ microenvironment interactions.
- Understanding vessel co-option is crucial for predicting patient prognosis and treatment response.
- Targeting the biological drivers of vessel co-option may lead to novel therapeutic strategies for cancer.
Related Concept Videos
Mechanism of Angiogenesis
6.6K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.6K
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Development of Blood Vessels
1.3K
The development of the vascular system in a fetus is a complex and intricate process that begins as early as 15 to 16 days post-conception. This process starts outside the embryo, specifically in the mesoderm of the yolk sac, chorion, and connecting stalk. Approximately two days later, the formation of blood vessels occurs within the embryo itself.
The initial formation of this system is facilitated by the small amount of yolk present in the ovum and yolk sac. Blood vessels originate from...
The initial formation of this system is facilitated by the small amount of yolk present in the ovum and yolk sac. Blood vessels originate from...
1.3K
Metastasis
6.3K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K

